About Clovis Oncology
Clovis Oncology is a company based in Boulder (United States) founded in 2009. It operates as a B2B. Clovis Oncology has raised $423.26 million across 6 funding rounds from investors including State Street, Frazier Healthcare Partners and Abingworth. The company has 280 employees. Clovis Oncology has completed 1 acquisition, including EOS Milano. Clovis Oncology operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Boulder, United States
- Employees 280
- SectorsHealthcare
- Website clovisoncology.com
- Social X
- Legal Name Clovis Oncology, Inc.
- Total Equity Funding$423.26M (USD)
in 6 rounds
- Latest Funding Round$7.5M (USD), Series C
Nov 2020
- InvestorsState Street
& 7 more
- Employee Count280
- Investments & Acquisitions
Funding Insights of Clovis Oncology
Clovis Oncology has successfully raised a total of $423.26M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $7.5 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $423.26M
- Total Rounds 6
- Last Round Series C — $7.5M
- First Round $20M
(Jun 2011)
- Investors Count 8
All 6 funding rounds of Clovis Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $7.5M | Series C | – | – | – |
| Nov 2020 | $57.5M | Series C | – | – | – |
| Jul 2019 | – | Series C | – | – | |
| May 2018 | $146.3M | Series C | – | – | |
| Nov 2013 | $191.96M | Series B | – | – | – |
| Jun 2011 | $20M | Series A | – | – | – |
8 investors in total: 8 institutional.
Investors in Clovis Oncology
Clovis Oncology has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include State Street, Frazier Healthcare Partners and Abingworth.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science & tech focused VC firm investing in the US | – | domainvc.com | Princeton, United States | |
Venture capital investments are offered to startups by NEA. | – | nea.com | Menlo Park, United States | |
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | – | versantventures.com | - | |
US Life-Sciences sectors are targeted for investment by Aberdare Ventures. | – | aberdare.com | San Francisco, United States | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
- | – | proquestvc.com | - | |
Financial services are provided to asset managers worldwide. | 1792 | statestreet.com | Boston, United States |
Investor details for Clovis Oncology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Clovis Oncology
31 people are tracked at Clovis Oncology (7 in leadership, 9 in board & advisors, 15 in team); the tracked headcount is 280.
| Name | Role | Group |
|---|---|---|
Chris Karlovich | Associate Director | Leadership |
Karen McLachlan | Director, Clinical Science | Leadership |
Patrick J. Mahaffy | President & CEO | Leadership |
James Samuda | Head Of Commercial Operations | Leadership |
Lindsey Rolfe | EVP, Clinical Development and Pharmacovigilance & Chief Medical Officer | Leadership |
Peter Leopardi | Senior Vice President, U.s. Commercial | Leadership |
Nathalie Lvoff | Public Policy Communication And Market Access Director France And Benelux | Leadership |
Ginger L. Graham | Director | Board & advisors |
Paul Klingenstein | Director | Board & advisors |
Edward J. Mckinley | Director | Board & advisors |
Thorlef Spickschen | Director | Board & advisors |
Brian G. Atwood | Director | Board & advisors |
Richard A. Fair | Director | Board & advisors |
Keith Flaherty | Director | Board & advisors |
Ronit Simantov | Director | Board & advisors |
James Blair | Director | Board & advisors |
Tom Daratony | Territory Manager | Team |
John Dempsey | Territory Manager | Team |
Harrington | Territory Account Manager | Team |
Vern L. | Information Technology Manager | Team |
11 more people are available in the full profile.
Complete people profiles for Clovis Oncology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Clovis Oncology
Clovis Oncology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include EOS Milano.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of Lucitanib - an oral small molecule tyrosine kinase inhibitor to prevent tumor angiogenesis | eosmilano.com | Milano, Italy | 2005 | Nov 2013 | $200M |
Complete acquisition details for Clovis Oncology
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Clovis Oncology
4 dated milestones of Clovis Oncology across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Clovis Oncology is founded.
- Funding First funding round of $20.0M.
- Acquisition Acquires EOS Milano.
- Funding Latest funding round, Series C, of $7.5M.
Competitors of Clovis Oncology
Clovis Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| adacap.com | 2002 | Saint Genis Pouilly, France | $56.13M | – | Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. |
Detailed competitors of Clovis Oncology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Clovis Oncology
Websites that share an audience with Clovis Oncology (clovisoncology.com).
Websites whose visitors overlap most with Clovis Oncology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pumabiotechnology.com | 100% | 9.6K | #2,574,682 | View details | |
| arraybiopharma.com | 92% | – | – | View details | |
| fresenius-kabi-oncology.com | 87% | 1.7K | #9,088,911 | View details |
Latest news on Clovis Oncology
Complete news archive for Clovis Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Clovis Oncology
10 companies that operate in the same segment as Clovis Oncology (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Clovis Oncology
Clovis Oncology was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Clovis Oncology is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Clovis Oncology is a funded company, having raised a total of $423.26M across 6 funding rounds to date. The company's 1st funding round was a Series A of $20M, raised on Jun 2011.
Clovis Oncology has 280 employees.
Clovis Oncology, based in Boulder, focuses on providing healthcare solutions, advancing biotech innovations, oncology, and immunotherapy. Develops innovative immunotherapy drugs for cancer treatment. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
Clovis Oncology's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Clovis Oncology has made 1 acquisition, including EOS Milano.
Clovis Oncology has 8 investors. Key investors include State Street, Frazier Healthcare Partners, Abingworth, Domain Associates, and NEA.
Clovis Oncology operates through Clovis Oncology, Inc..